168 related articles for article (PubMed ID: 23041157)
1. Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation.
Capucha V; Mendes E; Francisco AP; Perry MJ
Bioorg Med Chem Lett; 2012 Nov; 22(22):6903-8. PubMed ID: 23041157
[TBL] [Abstract][Full Text] [Related]
2. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
[TBL] [Abstract][Full Text] [Related]
3. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
[TBL] [Abstract][Full Text] [Related]
4. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
5. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Springer CJ; Niculescu-Duvaz I
Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
[TBL] [Abstract][Full Text] [Related]
6. Dopamine- and tyramine-based derivatives of triazenes: activation by tyrosinase and implications for prodrug design.
Perry MJ; Mendes E; Simplício AL; Coelho A; Soares RV; Iley J; Moreira R; Francisco AP
Eur J Med Chem; 2009 Aug; 44(8):3228-34. PubMed ID: 19386398
[TBL] [Abstract][Full Text] [Related]
7. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
8. Towards an efficient prodrug of the alkylating metabolite monomethyltriazene: synthesis and stability of N-acylamino acid derivatives of triazenes.
Perry Mde J; Carvalho E; Rosa E; Iley J
Eur J Med Chem; 2009 Mar; 44(3):1049-56. PubMed ID: 18687506
[TBL] [Abstract][Full Text] [Related]
9. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
Springer CJ; Niculescu-Duvaz I; Pedley RB
J Med Chem; 1994 Jul; 37(15):2361-70. PubMed ID: 8057284
[TBL] [Abstract][Full Text] [Related]
10. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy.
Mancini L; Davies L; Friedlos F; Falck-Miniotis M; Dzik-Jurasz AS; Springer CJ; Leach MO; Payne GS
NMR Biomed; 2009 Jun; 22(5):561-6. PubMed ID: 19259950
[TBL] [Abstract][Full Text] [Related]
11. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
[TBL] [Abstract][Full Text] [Related]
12. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.
Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M
J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634
[TBL] [Abstract][Full Text] [Related]
13. New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
Dowell RI; Springer CJ; Davies DH; Hadley EM; Burke PJ; Boyle FT; Melton RG; Connors TA; Blakey DC; Mauger AB
J Med Chem; 1996 Mar; 39(5):1100-5. PubMed ID: 8676345
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
[TBL] [Abstract][Full Text] [Related]
15. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).
Monks NR; Calvete JA; Curtin NJ; Blakey DC; East SJ; Newell DR
Br J Cancer; 2000 Jul; 83(2):267-9. PubMed ID: 10901381
[TBL] [Abstract][Full Text] [Related]
16. Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy.
Khan TH; Eno-Amooquaye EA; Searle F; Browne PJ; Osborn HM; Burke PJ
J Med Chem; 1999 Mar; 42(6):951-6. PubMed ID: 10090777
[TBL] [Abstract][Full Text] [Related]
17. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
[TBL] [Abstract][Full Text] [Related]
18. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
[TBL] [Abstract][Full Text] [Related]
19. Diethylstilbestrol glutamate as a potential substrate for ADEPT.
Pedone E; Searle F; Brocchini S
J Drug Target; 2006 Jul; 14(6):437-43. PubMed ID: 17092843
[TBL] [Abstract][Full Text] [Related]
20. Self-immolative anthracycline prodrugs for suicide gene therapy.
Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
